We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ERS Genomics and genOway Enter CRISPR/Cas9 Agreement
Product News

ERS Genomics and genOway Enter CRISPR/Cas9 Agreement

ERS Genomics and genOway Enter CRISPR/Cas9 Agreement
Product News

ERS Genomics and genOway Enter CRISPR/Cas9 Agreement


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "ERS Genomics and genOway Enter CRISPR/Cas9 Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier have announced a non-exclusive license agreement granting genOway past and future access to ERS Genomics’ CRISPR/Cas9 patent portfolio.

“CRISPR/Cas9 is a powerful in vivo genome engineering tool that has revolutionized many research areas. At ERS, we are committed to make this technology broadly available. We are very pleased to support genOway’s development with this license agreement,” said Eric Rhodes, CEO of ERS Genomics.

“This license from ERS will broaden our CRISPR IP portfolio, and widen our rodent models offering,” said Alexandre Fraichard, CEO of genOway. “This will ultimately enable us to pursue our mission of providing the scientific community with scientifically highly relevant preclinical models paired with guaranteed freedom to operate, in particular for commercial applications.”


Advertisement